Summary of Study ST001720

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001053. The data can be accessed directly via it's Project DOI: 10.21228/M8KQ59 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001720
Study TitleMetabolomics Analysis of ACTG Cohort -Update (part-II)
Study TypeMetabolomics Analysis
Study SummaryGlobal metabolomics analysis of ACTG cohort
Institute
Wistar Institute
Last NameAbdel-Mohsen
First NameMohamed
Address3601 Spruce St, Philadelphia, PA 19104
Emailmmohsen@wistar.org
Phone215-898-6008
Submit Date2021-01-07
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2021-05-25
Release Version1
Mohamed Abdel-Mohsen Mohamed Abdel-Mohsen
https://dx.doi.org/10.21228/M8KQ59
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001053
Project DOI:doi: 10.21228/M8KQ59
Project Title:Non-Invasive Plasma Glycomic and Metabolic Biomarkers of Post-treatment Control of HIV
Project Summary:Non-invasive biomarkers that predict HIV remission after antiretroviral therapy (ART) interruption are urgently needed. Such biomarkers can improve the safety of analytic treatment interruption (ATI) and provide mechanistic insights into the pathways involved in post-ART HIV control. We identified plasma glycomic and metabolic signatures of time-to-viral-rebound and probability-of-viral-rebound using samples from two independent cohorts. These samples include a large number of post-treatment controllers, a rare population demonstrating sustained virologic suppression after ART-cessation. The signatures remained significant after adjusting for key demographic and clinical confounders. We also confirmed a mechanistic link between biomarkers and HIV latency reactivation and myeloid inflammation in vitro. Finally, machine learning algorithms selected sets of biomarkers that predict time-to-viral-rebound with 74-76% capacity and probability-of-viral-rebound with 97.5% capacity. In summary, we fill a major gap in HIV cure research by identifying non-invasive biomarkers, with potential functional significance, that predict duration and probability of viral remission after treatment interruption.
Institute:The Wistar Institute
Last Name:Abdel-Mohsen
First Name:Mohamed
Address:3601 Spruce St, Philadelphia, PA 19104
Email:mmohsen@wistar.org
Phone:215-898-6008

Subject:

Subject ID:SU001797
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Non controllers (NC=1) or post-treatment controller (PTC=2) Gender Race/ethnicity
SA161941321 F Black
SA161942171 F Hispanic
SA16194311 F Hispanic
SA161944501 F White
SA161945301 F White
SA161946281 F White
SA1619471641 F White
SA161948401 M Black
SA161949531 M Black
SA1619501711 M Black
SA161951691 M Black
SA161952371 M Black
SA161953451 M Black
SA161954661 M Black
SA161955161 M Black
SA161956761 M Hispanic
SA1619572031 M Hispanic
SA1619582051 M Hispanic
SA16195961 M Hispanic
SA161960581 M Hispanic
SA16196141 M Hispanic
SA1619621671 M White
SA1619632001 M White
SA1619641621 M White
SA1619652081 M White
SA16196691 M White
SA1619671801 M White
SA1619681731 M White
SA161969101 M White
SA1619701751 M White
SA1619711781 M White
SA1619721681 M White
SA161973881 M White
SA161974201 M White
SA161975561 M White
SA161976631 M White
SA161977471 M White
SA161978231 M White
SA161979421 M White
SA161980431 M White
SA161981341 M White
SA161982131 M White
SA161983811 M White
SA161984741 M White
SA161985711 M White
SA161986841 M White
SA161987781 M White
SA1619881402 F Black
SA1619891192 F Black
SA1619901562 F Black
SA1619911082 F Black
SA1619921142 F Hispanic
SA1619931112 F White
SA1619941852 M Black
SA1619951022 M Black
SA161996912 M Black
SA161997942 M Hispanic
SA1619981462 M Hispanic
SA1619991542 M White
SA1620001922 M White
SA1620011962 M White
SA162002992 M White
SA1620031832 M White
SA1620041892 M White
SA1620051432 M White
SA1620061492 M White
SA1620071822 M White
SA1620081592 M White
SA1620091362 M White
SA1620101502 M White
SA1620111322 M White
SA1620121282 M White
SA1620131252 M White
SA1620141302 M White
SA162015QC1-7NA NA NA
SA162016QC1-8NA NA NA
SA162017QC1-6NA NA NA
SA162018QC1-4NA NA NA
SA162019QC1-2NA NA NA
SA162020QC1-3NA NA NA
SA162021QC1-5NA NA NA
Showing results 1 to 81 of 81

Collection:

Collection ID:CO001790
Collection Summary:Analyses were performed from banked plasma samples of two different cohorts that underwent analytical treatment interruption (ATI): (1) Philadelphia Cohort and (2) ACTG cohort. In the Philadelphia cohort, HIV+ individuals on suppressive ART underwent an open-ended ATI without concurrent immunomodulatory agents. The ACTG cohort combined 74 HIV-infected ART-suppressed participants who underwent ATI from six ACTG ATI studies (ACTG 371,28 A5024,29 A5068,30 A5170,31 A5187,32 and A519733). 27 of these 74 individuals exhibited a PTC phenotype post-ATI, i.e. these individuals remained off ART for ≥24 weeks post-treatment interruption, sustained virologic control for at least 24 weeks, maintained viral load (VL) ≤400 copies for at least 2/3 of time points, had plasma drug level testing performed, and had no evidence of spontaneous control pre-ART. The remaining 47 cohort members were non-controllers (NCs) who exhibited virologic rebound before meeting PTC criteria. These two groups were matched for gender, age, % treated at the early stage of HIV infection, ART duration, pre-ATI CD4 count, and ethnicity. All analyses were performed on samples collected immediately before ATI in both cohorts.
Sample Type:Blood (plasma)

Treatment:

Treatment ID:TR001810
Treatment Summary:No treatment

Sample Preparation:

Sampleprep ID:SP001803
Sampleprep Summary:Briefly, polar metabolites were extracted from 50 µl plasma samples with 500 µl ice-cold 80% methanol, and deproteinated supernatants were stored at -80 °C prior to analysis. A quality control (QC) sample was generated by pooling equal volumes of all samples after extraction.
Processing Storage Conditions:On ice
Extract Storage:-80℃

Chromatography:

Chromatography ID:CH002071
Chromatography Summary:Hydrophilic interaction liquid chromatography (HILIC) was performed at 0.2 ml/min on a ZIC-pHILIC column (2.1 mm × 150 mm, EMD Millipore) at 45 °C. Solvent A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide, pH 9.2, and solvent B was acetonitrile. The gradient was 85% B for 2 min, 85% B to 20% B over 15 min, 20% B to 85% B over 0.1 min, and 85% B for 8.9 min. The autosampler was held at 4 °C. For each analysis, 4 µl of sample was injected.
Instrument Name:Thermo Vanquish
Column Name:SeQuant ZIC-pHILIC (150 x 2.1mm,5um)
Flow Gradient: 85% B for 2 min, 85% B to 20% B over 15 min, 20% B to 85% B over 0.1 min, and 85% B for 8.9 min.
Solvent A:100% water; 20 mM ammonium carbonate; 0.1% ammonium hydroxide, pH 9.3
Solvent B:100% acetonitrile
Chromatography Type:HILIC

Analysis:

Analysis ID:AN002803
Analysis Type:MS
Chromatography ID:CH002071
Num Factors:13
Num Metabolites:226
Rt Units:Minutes
Units:Peak Area
  logo